Cubist Hits Hospira With Patent Suit Over Generic Cubicin
Lexington, Mass.-based Cubist filed the suit after Hospira allegedly sought U.S. Food and Drug Administration approval to make and market a generic version of Cubicin in violation of Cubist’s patent rights.
“Hospira’s submission of [abbreviated new drug application] No. 202587 for the purpose of obtaining approval to engage in the...
To view the full article, register now.